ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Konishi, T.
Right arrow Articles by Yamato, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Konishi, T.
Right arrow Articles by Yamato, Y.

The Annals of Thoracic Surgery, Vol 56, 101-103, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Preoperative use of erythropoietin for cardiovascular operations in anemia

T Konishi, T Ohbayashi, T Kaneko, T Ohki, Y Saitou and Y Yamato
Division of Cardiovascular Surgery, Gunma Prefectural Maebashi Hospital, Japan.

Erythropoietin was used in 10 patients undergoing elective cardiovascular operations who were compromised with anemia. Initially, their blood hemoglobin levels were less than 10 g/dL (range, 7.5 to 9.9 g/dL). Erythropoietin (600 to 700 units/kg per week) was administered intravenously or subcutaneously for about 2 to 12 weeks. Blood hemoglobin levels increased in each patient (11.0 to 14.5 g/dL) until the day operation, and during this course autologous blood donations (400 to 1,200 mL) were obtained from 8 patients. As a result, homologous blood transfusions were needed in only 1 patient in whom erythropoietin treatment was interrupted for other reasons. All these patients were discharged without event, and no adverse effects due to erythropoietin were found. Although the causes of anemia were not specified in some of these patients, it was noteworthy that erythropoietin was effective even in a patient with hypoplastic bone marrow. Subcutaneous use was assumed to be especially favorable in managing anemic patients, in whom preoperative erythropoietin treatment could be continued for up to 82 days. We conclude that erythropoietin would be beneficial for the anemic population to secure homologous- blood-free operations.


This article has been cited by other articles:


Home page
 CirculationHome page
R. J. Sommer, Z. M. Hijazi, and J. F. Rhodes Jr
Pathophysiology of Congenital Heart Disease in the Adult: Part I: Shunt Lesions
Circulation, February 26, 2008; 117(8): 1090 - 1099.
[Full Text] [PDF]

Home page
 Br J AnaesthHome page
V. Casati, A. D'Angelo, L. Barbato, D. Turolla, F. Villa, M. A. Grasso, A. Porta, and F. Guerra
Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery
Br. J. Anaesth., September 1, 2007; 99(3): 349 - 352.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. YazicioGlu, S. Eryilmaz, M. Sirlak, M. B. Inan, A. Aral, R. Tasoz, N. T. Eren, B. Kaya, and H. Akalin
Recombinant human erythropoietin administration in cardiac surgery
J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 741 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Kiyama, N. Ohshima, T. Imazeki, and T. Yamada
Autologous blood donation with recombinant human erythropoietin in anemic patients
Ann. Thorac. Surg., November 1, 1999; 68(5): 1652 - 1656.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The Society of Thoracic Surgeons.